News

The main objective of the deal will be to develop a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of HCV. An initial regimen that is planned

As part of the deal, BioNTech will provide proprietary antibodies against key immunomodulatory targets that activate the immune system against cancer, while Genmab will provide access to its

The Japanese firm will continue to distribute the seasonal influenza vaccine, Influenza HA Vaccine ‘SEIKEN’, manufactured by Denka Seiken. The Preventive Vaccination Law in Japan noted that elders

The company intends to begin a Phase II clinical trial with Resunab in adults with CF within the next 90 days. CF primarily affects the lungs and digestive

Tipifarnib is an inhibitor of farnesylation, a major cell signaling process implicated in cancer initiation and development. The HRAS protein is involved in regulating cell division in response

The investigator-initiated trial is sponsored by Stanford University and its primary objective is to evaluate the safety and efficacy of AbGn-168H in patients with steroid refractory aGvHD in

As part of the deal, both the firms will evaluate the efficacy of combining somatostatin analogs’ neuroendocrine tumor targeting capabilities with the cell-killing potential of Areva Med’s lead-212

Namzaric is a once-daily, fixed-dose combination of memantine hydrochloride extended-release (a NMDA receptor antagonist), and donepezil hydrochloride (an acetylcholinesterase inhibitor). Last December, the US Food and Drug Administration

The collaboration also aligns with Genzyme’s early-stage MS research programs involving neuroprotection and CNS repair. The neurodegeneration observed in MS is not directly targeted by currently available treatments